Bharat Motwani, MD
Infectious Disease · Davenport, IANPI 1902885445
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $990 of the $1,483 with a category attached, or 66.8%. 15 manufacturers reported payments, led by Astellas Pharma US Inc at 25.4% of the total. Reporting peaked in 2019 at $476 and has fallen 94.3% since, to $27 in 2025.
Across 62 payments — averaging $23.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$377
- Viiv Healthcare Company$197
- Pfizer$192
- Gilead$134
- Merck$130
- AbbVie$122
- plus $332 from 9 others
What the payments were for
- Consulting fees$1007%
- Food & beverage$99067%
- Education$39327%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 4 | $377 |
| Viiv Healthcare Company | 8 | $197 |
| Pfizer | 9 | $192 |
| Gilead | 9 | $134 |
| Merck | 9 | $130 |
| AbbVie | 8 | $122 |
| Comsort, Inc | 1 | $100 |
| Insmed, Inc. | 5 | $84 |
| Johnson & Johnson | 2 | $42 |
| La Jolla Pharmaceutical Company | 2 | $27 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIVEXTRO$100
How this compares
$1,483 in reported general payments places this provider in the 85th percentile of 58 infectious disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 44 | $165,831 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 35 | $120,200 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 21 | $97,892 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 13 | $45,795 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 11 | $43,183 |
| DescovyEmtricitabine/Tenofov Alafenam | 16 | $36,556 |
| IsentressRaltegravir Potassium | 12 | $27,321 |
| PrezcobixDarunavir/Cobicistat | 11 | $24,562 |
| TivicayDolutegravir Sodium | 11 | $22,538 |
| Lupron DepotLeuprolide Acetate | 12 | $21,782 |
| Atazanavir Sulfate | 23 | $15,273 |
| Etravirine | 12 | $13,509 |
| JardianceEmpagliflozin | 11 | $6,611 |
| Rifampin | 12 | $2,408 |
| Fluconazole | 48 | $2,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Stribild, Descovy | $134 | $343,46292 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay | $197 | $68,33324 claims |
| MerckIsentress | $130 | $27,32112 claims |
| Johnson & JohnsonPrezcobix | $42 | $24,56211 claims |
| AbbVieLupron Depot | $122 | $21,78212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 58 infectious disease providers in Iowa.
Other infectious disease in Davenport
- Louis KatzDavenport$12K
- Felipe BarbosaDavenport$116
- Ravi VemuriDes Moines$16K
- Michael OhlIowa City$9K
- Upinder SinghIowa City$8K
- Karen BrustIowa City$4K
- Patricia WinokurIowa City$3K
- Daniel LampteySioux City$2K
- Ami PatelWaterloo$2K
- Aneesa AfrozeDes Moines$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.